Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dr Oxford Biotech Factory Co. Ltd. holds a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action, which is the only active prosecution matter for the company. This indicates a very specific and concentrated effort to protect its technological assets in this field.
The examination process involves 1 distinct examiner. This examiner is assigned to 1 distinct art unit, suggesting that the company's work in Biotechnology & Pharmaceuticals is focused on a particular technical niche. SASAN, ARADHANA is the busiest examiner for the portfolio. This examiner is currently managing the 1 pending office action that is active.
With a busiest examiner pending count of 1, the company's prosecution strategy is centralized. This means that the company's legal team is interacting with only 1 distinct examiner to advance its patent applications. While this simplifies the prosecution process, it also means that the company's immediate goals in the Biotechnology & Pharmaceuticals sector are tied to a single examiner's review.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SASAN, ARADHANA | 1 | 64.5% | +26.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18162038 | ANTI-CANCER COMPOSITION AND USE THEREOF | SASAN, ARADHANA | 23d |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18162038 | ANTI-CANCER COMPOSITION AND USE THEREOF | SASAN, ARADHANA | 1615 | §103 | Final Rejection | 23d | Pending | Jan 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial